683 Capital Management LLC Purchases New Position in Shattuck Labs, Inc. (NASDAQ:STTK)

683 Capital Management LLC purchased a new position in Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,050,000 shares of the company's stock, valued at approximately $1,270,000. 683 Capital Management LLC owned 2.20% of Shattuck Labs at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in STTK. JPMorgan Chase & Co. boosted its stake in Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company's stock worth $96,000 after purchasing an additional 10,667 shares during the period. Takeda Pharmaceutical Co. Ltd. bought a new position in shares of Shattuck Labs in the fourth quarter valued at approximately $624,000. Geode Capital Management LLC boosted its position in shares of Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company's stock valued at $3,184,000 after acquiring an additional 8,133 shares during the period. Barclays PLC grew its stake in Shattuck Labs by 299.5% during the third quarter. Barclays PLC now owns 54,311 shares of the company's stock valued at $189,000 after acquiring an additional 40,717 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Shattuck Labs during the 4th quarter worth approximately $30,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Stock Performance

STTK traded up $0.00 during trading on Wednesday, reaching $0.87. The stock had a trading volume of 26,759 shares, compared to its average volume of 376,056. The business has a 50-day moving average of $1.03 and a 200-day moving average of $1.15. Shattuck Labs, Inc. has a one year low of $0.69 and a one year high of $11.76. The stock has a market cap of $41.72 million, a PE ratio of -0.57 and a beta of 1.74.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Equities research analysts forecast that Shattuck Labs, Inc. will post -1.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Leerink Partnrs upgraded shares of Shattuck Labs to a "strong-buy" rating in a research report on Monday, March 17th. Needham & Company LLC restated a "hold" rating on shares of Shattuck Labs in a research report on Thursday, March 27th. HC Wainwright restated a "neutral" rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Finally, Leerink Partners assumed coverage on Shattuck Labs in a report on Monday, March 17th. They set an "outperform" rating and a $4.00 price objective for the company. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Shattuck Labs has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.